
Oxidative Coupling of (-)-Sclareol and Related Diols Leading to Oxepane Terpenoids

Hanane Bouanou,^a Juan A. Gil,^a Ramón Alvarez-Manzaneda,^b Rachid Chahboun^{*a} and Enrique Alvarez-Manzaneda^{*a}

^aDepartamento de Química Orgánica, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain ^bÁrea de Química Orgánica, Departamento de Química y Física, Universidad de Almería, 04120 Almería, Spain.



ABSTRACT: Treatment of (-)-sclareol and related compounds with lead tetraacetate affords tetracyclic compounds bearing a 2,8dioxabicyclo[5.2.0]nonane moiety, with complete regio- and stereoselectivity. This process, which is also applicable to 1,5-diols with a similar substitution pattern, facilitates the development of efficient syntheses towards oxepane terpenoids, such as aplysistatin derivatives.


Natural products are frequently utilized as the starting material for synthesizing valuable compounds, providing various advantages in this respect. These processes make use of the stereochemistry and other structural features of the natural precursor, which makes it feasible to achieve the target compound in an efficient and economical way. One such natural compound is (-)-sclareol (1).¹ This labdane diterpene, which is the main component of the aerial parts of the clary sage Salvia sclarea, satisfies all the requisites for this purpose. Compound 1, which has a *trans*-decalinic system with five stereogenic centres, is an inexpensive, commerciallyavailable compound. The use of this diterpene as a starting material usually involves the degradative oxidation of the carbon side chain and the suitable transformation of the C-8 hydroxyl group. The oxidant systems most often utilized for this purpose are RuCl₃/3H₂O/NaIO₄² or OsO₄/NaIO₄,^{3,5a} or the more classic reagent KMnO4.4

Continuing our research into the oxidation of (-)-sclareol (1), we were interested in exploring processes involving radical species, which have received very little research attention. Indeed, only two articles in this respect have been published. Decorzant et al. reported the preparation of the odorant (-)-ambrox from diterpene 1. Treatment with hydrogen peroxide in an acid medium produced a mixture of hydroperoxides and manoyl oxides; the degradation of 13-hydroperoxide epimers with Fe (II) and Cu (II) salts, via an alkoxy radical, afforded the target compound in 52% global

yield.⁵ In addition, our group described a very efficient synthesis of manoyl oxide,⁶ after treatment of diterpene **1** with cerium ammonium nitrate; the participation of oxygen radicals was postulated for the cyclization process.⁷ In general, chemical processes involving alkoxy radicals have been little studied, probably due to their high reactivity, particularly in the case of those derived from primary and secondary alcohols, and to the ready oxidation of this type of alcohols. Mihailovic reported the use of Pb(OAc)₄ to convert different types of alcohols into variable mixtures of cyclic ethers and other oxidation products.⁸

The treatment of (-)-sclareol (1) with $Pb(OAc)_4$ (1.5 eq) in dichloromethane at room temperature for 12 h gave the tetracyclic diether 2 in high yield (Scheme 1). When the reaction was performed in benzene, a mixture of compounds resulted. When $PhI(OAc)_2$ was utilized as the oxidant, the starting material remained unaltered.

Scheme 1. Reaction of (-)-sclareol (1) with Pb(OAc)₄.



This unexpected result prompted us to explore the use of this reaction for the efficient preparation of terpenes bearing an oxepane moiety.⁹ Some interesting examples of this type of compound are found in nature, including sesquiterpenes, such as the cytotoxic (-)-aplysistatin (**3**)¹⁰ and (+)-palisadin B (**4**),¹¹ the bromoditerpene **5**, and the related oxocane **6**,¹² the sesterterpene (+)-luffalactone (**7**)¹³ or the merosesquiterpene bis(sulfate)-cyclosiphonodictyol A (**8**).¹⁴ (Figure 1).






Figure 1. Some natural oxepane terpenes and related compounds.

In order to establish the scope of this oxidation, other diols with a substitution pattern similar to that of (-)-sclareol (1) were assayed (Table 1).

Table 1. Treatment of (-)-sclareol (1) and related diols with Pb(OAc)4.






^aThe relative stereochemistry of the resulting compounds was established on the basis of NOE experiments.

As can be seen, diols 1, 9, 11, 13 and 16 gave the corresponding diethers 2, 10, 12, 14, 15 and 17, having a 2,8dioxabicyclo[5.2.0]nonane moiety, with complete regio- and stereoselectivity. This process could involve the Pb(IV) approach to the carbon-carbon double bond, probably assisted by the allyl hydroxyl group,¹⁶ to produce a complex, which undergoes the attack of the C₈-hydroxyl group leading to intermediate II, which after C-O reductive elimination will gave the bicyclic ether 2 (Scheme 2). At this point, we cannot rule out the intermediacy of radical or cationic species.¹⁷ On the other hand, intermediates are not detected in the course of the reaction, and a concerted process should not be excluded. It is important to note that diol 18, the epimer of compound 16, remains unaltered under the reaction conditions; in this case, the tricylic intermediate similar to II cannot be formed, due to the 1,3-diaxial interaction between methyl groups. In the case of acyclic diol 19, the 2,8dioxabicyclo[5.2.0]nonane fragment is not present in the final compound, probably due to the flexibility of the monocyclic oxepane, which is unfavourable to the formation of the oxetane ring.

Scheme 2. A possible transformation of (-)-sclareol (1) into tetracyclic ether 2 *via* intermediate **II**.



After obtaining the tetracyclic diether **2**, we studied the oxetane ring opening, in order to prepare synthetic intermediates of oxepane terpenoids related to compounds **3-8**. We then examined the nucleophilic oxetane ring opening of compounds **2** and **17**. The most significant results obtained are shown in table 2.

Table 2. Nucleophilic oxetane ring opening for compounds 2 and 17.



Entry	Conditions	t	Product
1	2,CH3COCl, N,N- dimethylaniline, CH2Cl2, rt	72h	OAc 1 (80%)
2	2, POCl ₃ , pyridine, 0 °C	15h	22 (56%)
3	2 , SOCl ₂ , NEt ₃ , - 30 °C	3 h	Complex mixture
4	2 , LiBr, DMF, 70 °C	72h	он Н 23 (30%)
5	2 , CH ₂ =CHMgBr, THF, reflux	72h	Starting material
6	2, MgBr ₂ , toluene, reflux	15h	Complex mixture


7	2, TMSOTf, CH2Cl2, 0 °C,	Et2NPr ⁱ ,	5min	С (97%)
8	2, TBSOTf, CH2Cl2, 0 °C,	Et2NPr ⁱ ,	5min	OTBS
9	17 , TBSOTf, CH ₂ Cl ₂ , 0 °C,	Et2NPr ⁱ ,	15min	25 (97%)

As can be seen, even though the treatment of diether **2** with LiBr gave alcohol **23** in low yield (entry 4), this compound was obtained in high yield when the oxetane ring opening was realized with TMSOTF (entry 7).

Compounds **21-25** appear to be suitable intermediates to prepare oxepane terpenoids related to the above natural products.


Thus, the chloroderivative **22** was transformed into chloroalcohol **27a**, the corresponding 3-debromoderivative of natural oxepane **5** (Scheme 3).

Scheme 3. Synthesis of chloroalcohols 27a-b from oxepane 22.



The homoallyl alcohol moiety presented by compounds **21** and **23-25** can also be easily converted into the γ -butyrolactone fragment of aplysistatins and related compounds. Thus, oxepane **24** was efficiently transformed into lactone **31**, a tetracyclic analogue of 3-debromoaplysistatin (Scheme 4).

Scheme 4. Synthesis of lactone 31 from oxepane 24.



Following the same synthetic sequence, compound **25** could be readily converted into the corresponding tricyclic lactone (3-debromoaplysistatin).

In summary, (-)-sclareol (1) and related 1,5-diols with a similar substitution pattern undergo an oxidative coupling process after treatment with lead tetraacetate, affording diethers bearing a 2,8-dioxabicyclo[5.2.0]nonane moiety. The oxetane ring opening of these compounds provides suitable intermediates for synthesizing oxepane terpenoids, such as aplysistatin derivatives.

EXPERIMENTAL SECTION

General methods.

Unless stated otherwise, reactions were performed in oven-dried glassware under an argon atmosphere using dry solvents. Solvents were dried as follows: THF and MeOtBu-over Na-benzophenone, benzene over Na, DCM and MeOH over CaH₂. Dimethylformamide (DMF) was dried over 4Å molecular sieves. Thin-layer chromatography (TLC) was performed using F254 precoated plates (0.25 mm) and visualized by UV fluorescence quenching and phosphomolybdic acid solution staining. Flash chromatography was performed on silica gel (230-400 mesh) Chromatography separations were carried out by conventional column on silica gel 60 (230-400 Mesh), using Hexanes-MeOtBu (H-E) mixtures of increasing polarity.¹H and ¹³C NMR spectra were recorded at 500 MHz and 125 MHz, respectively. CDCl₃ was treated with K₂CO₃. Chemical shifts (δ H) are quoted in parts per million (ppm) referenced to the appropriate residual solvent peak and tetramethylsilane. Data for ¹H NMR spectra are reported as follows: chemical shift (\delta ppm) (multiplicity, coupling constant (Hz), integration), with the abbreviations s, br s, d, br d, t, q, and m denoting singlet, broad singlet, doublet, broad doublet, triplet, quartet and multiplet respectively. J = coupling constant in Hertz (Hz). Data for ¹³C NMR spectra are reported in terms of chemical shift relative to Me₄Si (δ 0.0) and the signals were assigned utilizing DEPT experiments and on the basis of heteronuclear correlations.Infrared spectra (IR) were recorded as thin films or as solids on a FTIR spectrophotometer with samples between sodium chloride plates or as potassium bromide pellets and are reported in frequency of absorption (cm⁻¹). Only selected absorbances (v_{max}) are reported. ($[\alpha]^D$) measurements were carried out in a polarimeter; utilizing a 1dm length cell and CHCl3 as a solvent. Concentration is expressed in mg/mL. HRMS were recorded on a spectrometer, utilizing a quadrupole MS/MS analyzer, and using FAB with thioglicerol or glycerol matrix doped in NaI 1%.

General procedure for the reaction of diols with $Pb(OAc)_4$. Lead tetraacetate (2 mmol) was added to a solution of diol (2 mmol) in dichloromethane (10 mL) and the resulting mixture was stirred at room temperature for the specified time, and the course of the reaction was monitored by TLC. When the starting material was consumed, the mixture was filtered on a silicagel pad and the solvent was evaporated. The crude residue was dissolved in ether (10 mL) and the organic solution was successively washed with 5% aq. NaHSO₃ (3 x 10 mL), H₂O (4 x 10 mL) and brine (10 mL). The organic phase was dried over anh. Na₂SO₄ and evaporated to give the bicyclic ether.

(4aS, 6aR, 7aR, 9aS, 11aR, 11bS)-4, 4, 6a, 9a, 11b-Pentamethyltetradecahydro-1H-naphtho[2, 1-b]oxeto [2, 3f]oxepine (2). Colourless oil, 963 mg, 97%. [α]_D²⁵ +6.4 (c 1.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.78 (s, 3H), 0.81 (s, 3H), 0.86 (s, 3H), 1.10 (ddd, *J* = 16.8, 13.3, 4.2 Hz, 1H), 1.27 (s, 3H), 1.40 (s, 3H), 1.33 - 1.69 (m, 14H), 2.51 (ddd, *J* = 17.4, 17.1, 6.6 Hz, 1H), 4.16 (dd, *J* = 5.8, 3.4 Hz, 1H), 4.19 (dd, *J* = 7.2, 3.4 Hz, 1H), 4.68 (dd, *J* = 7.2, 5.8 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ :□ 15.4 (CH₃), 18.7 (CH₂), 18.7 (CH₂), 20.2 (CH₂), 21.5 (CH₃), 22.6 (CH₃), 23.7 (CH₃), 31.7 (CH₂), 33.3 (C), 33.4 (CH₃), 38.4 (C), 38.7 (CH₂), 40.3 (CH₂), 41.7 (CH₂), 52.4 (CH), 56.4 (CH), 71.5 (CH), 72.0 (CH₂), 79.5 (C), 90.4 (C). IR (film): 1594, 1457, 1386, 1214, 1160, 1103, 1084, 973, 926, 875, 772, 665 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₀H₃₄O₂Na (M+Na+) 329.2457, found: 329.2463.

((4*S*,4a*R*,6a*R*,7a*R*,9a*R*,11a*R*,11b*S*)-4,6a,9a,11b-Tetramethyltetradecahydro-1H-naphtho[2,1-b]oxeto[2,3-

f]oxepin-4-yl)methanol (10). Colourless oil, 198 mg, 95%. [α] $_{\rm D}^{25}$ +7.06 (c 0.11, CHCl₃). ¹H- NMR (CDCl₃, 500 MHz) δ : 0.82 (s, 3H), 0.99 (s, 3H), 1.27 (s, 3H), 1.43 (s, 3H), 0.88 -1.81 (m, 15H), 2.54 (td, *J* = 11.9, 11.4, 7.5 Hz, 2H), 3.44 (d, *J* = 10.9 Hz, 1H), 3.69 (d, *J* = 10.9 Hz, 1H), 4.18 (dd, *J* = 5.9, 3.4 Hz, 1H), 4.22 (dd, *J* = 7.3, 3.4 Hz, 1H), 4.70 (dd, *J* = 7.3, 5.9 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz,) δ : 15.9 (CH₃), 18.4 (CH₂), 18.9 (CH₂), 20.4 (CH₂), 22.7 (CH₃), 23.6 (CH₃), 27.0 (CH₃), 31.7 (CH₂), 35.4 (CH₂), 38.4 (C), 38.6 (C), 39.1 (CH₂), 40.4 (CH₂), 79.3 (C), 90.2 (C). IR (film): 2959, 1426, 1255, 1125, 1075, 960, 754, 613 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₀H₃₄O₃Na (M+Na⁺) 345.2406, found: 345.2398.

(4*aS*, 5*S*, 6*aR*, 7*aR*, 9*aR*, 11*aR*, 11*bS*)- 4, 4, 6a, 9a, 11b-Pentamethyltetradecahydro-1H-naphtho[2, 1-b]oxeto[2, 3f]oxepin-5-yl acetate (12). Colourless oil, 228 mg, 92%. [α] D^{25} +21.8 (c 0.6, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ :0.83 (s, 3H), 0.84 (s, 3H), 1.03 (s, 3H), 1.23 (s, 3H), 1.40 (s, 3H), 0.88 – 2.21 (m, 14H), 2.02 (s, 3H), 4.25 (t, *J* = 5.9 Hz, 1H), 4.33 (dd, *J* = 5.9, 5.3 Hz, 1H), 4.52 (dd, *J* = 7.3, 5.3 Hz, 1H), 5.04 (dd, *J* = 7.3, 5.9 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ \Box : 17.4 (CH₃), 18.6 (CH₂), 19.7 (CH₂), 20.6 (CH₃), 22.0 (CH₃), 22.3 (CH₃), 24.7 (CH₃), 33.5 (C), 36.1 (CH₃), 38.6 (CH₂) 39.2 (C), 40.1 (CH₂), 43.1 (CH₂), 49.5 (CH₂), 58.1 (CH), 64.0 (CH), 70.9 (CH₂), 70.9 (CH), 72.8 (CH), 79.2 (C), 91.4 (C), 170.3 (C). IR (film): 1736, 1458, 1367, 1245, 1166, 1106, 1029, 975 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₂H₃₆O₄Na (M+Na⁺) 387.2511, found: 387.2526.

(4aS, 6aR, 7aS, 9aS, 11aR, 11bS)-4, 4, 6a, 7a, 9a, 11b-Hexamethyl tetradecahydro-1H-naphtho[2, 1-b]oxeto[2, 3f]oxepine (14). Colourless oil, 73 mg, 32%. $[\alpha]_D^{25}$ +7.4 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) &: 0.77 (s, 6H), 0.85 (s, 3H), 1.13 (s, 3H), 1.31 (s, 3H), 1.33 (s, 3H), 0.76 - 1.68 (m, 15H), 2.37 (m, 1H), 3.59 (d, J = 13.0 Hz, 1H), 3.73 (d, J = 13.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) &: 15.6 (CH₃), 18.6 (CH₂), 19.2 (CH₃), 19.5 (CH₂), 20.6 (CH₂), 21.3 (CH₃), 23.5 (CH₃), 33.3 (C), 37.9 (CH₂), 39.0 (CH₂), 39.2 (C), 39.9 (CH₂), 42.0 (CH₂), 49.4 (CH₃), 56.3 (CH), 58.0 (CH), 64.2 (C), 65.5 (CH₂), 65.9 (C), 72.8 (C), 79.4 (C). IR (film): 1594, 1458, 1385, 1261, 1082, 801 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₁H₃₆O₂Na (M+Na⁺) 343.2613, found: 343.2622.

(4aS, 6aR, 7aR, 9aS, 11aR, 11bS)-4, 4, 6a, 7a, 9a, 11b-Hexamethyltetradecahydro-1H-naphtho[2, 1-b]oxeto[2, 3-f]oxepine (15). Colourless oil, 94 mg, 41%. [α] $_{D}^{25}$ +5.4 (c 0.16, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : \Box 0.77 (s, 3H), 0.78 (s, 3H), 0.87 (s, 3H), 1.18 (s, 3H), 1.36 (s, 3H), 1.55 (s, 3H), 0.75 – 1.80 (m, 14H), 2.16 (m, 1H), 2.34 (m, 1H), 3.89 (d, J = 5.0 Hz, 1H), 4.40 (d, J = 5.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.0 (CH₃), 18.8 (CH₂), 19.6 (CH₂), 20.0 (CH₂), 21.9 (CH₃), 22.8 (CH₃), 25.2 (CH₃), 33.4 (CH₃), 38.4 (C), 39.2 (CH₂), 40.1 (CH₂), 41.8 (CH₂), 44.4 (CH₂), 49.4 (CH₂), 55.9 (CH), 64.7 (CH), 72.8 (C), 76.9 (C), 81.0 (C), 81.3 (CH₂), 92.5 (C). IR (film): 1706, 1460, 1379, 1194, 1086, 973 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₁H₃₆O₂Na (M+Na⁺) 343.2613, found: 343.2622.

(2aS,3aS,7aS)-3a,7,7,9a-Tetramethyldecahydro-2H-

benzo[b]oxeto[2,3-f]oxepine (17). Colourless oil, 249 mg, 93%. [α] $_{\rm D}^{25}$ -53.9 (c 0.12, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ : 0.83 (s, 3H), 0.92 (s, 3H), 1.29 (s, 3H), 1.41 (s, 3H), 1.20 – 1.65 (m, 11H), 4.18 – 4.24 (m, 2H), 4.70 (dd, *J* = 7.1, 5.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 19.8 (CH₂), 20.3 (CH₂), 20.9 (CH₃), 22.7 (2 x CH₃), 32.0 (CH₂), 33.2 (CH₃), 35.0 (C), 37.9 (CH₂), 41.9 (CH₂), 48.3 (CH), 71.7 (CH), 72.1 (CH₂), 79.5 (C), 90.4 (C). IR (film) : 1463, 1426, 1380, 1274, 1123, 1073, 1039, 959 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₁₅H₂₆O₂Na (M+Na⁺) 261.1830, found: 261.1842.

((2*R*, 3*S*)-3-Hydroxy-3, 7, 7-trimethyloxepan-2-yl) methyl acetate (20). Colourless oil, 267 mg, 50%. $[\alpha]_D^{25}$ -3.5 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) & 1.14 (s, 3H), 1.17 (s, 3H), 1.20 (s, 3H), 1.21 - 1.74 (m, 7H), 2.05 (s, 3H), 3.60 (dd, *J* = 9.0, 3.5 Hz, 1H), 3.97 (dd, *J* = 11.3, 9.0 Hz, 1H), 4.31 (dd, *J* = 11.3, 3.5 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) & 18.4 (CH₂), 21.2 (CH₃), 24.7 (CH₃), 27.2 (CH₃), 28.4 (CH₃), 40.4 (CH₂), 45.6 (CH₂), 63.9 (CH₂), 72.1 (C), 73.4 (CH), 75.8 (C), 171.2 (C). IR (film): 2968, 2928, 1739, 1599, 1463, 1368, 1123 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₁₂H₂₂O₄Na (M+Na⁺) 253.1416, found: 253.1404.

((4*S*,5a*R*,7a*S*,11a*S*,11b*R*)-5a,8,8,11a-Tetramethyl-3-methylenetetradecahydronaphtho[2,1-b]oxepin-4-

yl)methyl acetate (21). N,N-dimethylaniline (4 mL, 32 mmol) and CH₃COCl (1.15 mL, 16.3 mmol) were added to a solution of 2 (1 g, 3.26 mmol) in anhydrous CH_2Cl_2 (30 mL), and the mixture was kept stirring at room temperature under argon atmosphere for 72 h. Then, the reaction was quenched with

water (10 mL), and ether was added (30 mL). The organic solution was washed with 10% HCl (6 x 15 mL) and brine (2 x 15 mL), dried over anh. Na₂SO₄, and evaporate to yield **21** (900 mg, 80%). $[\alpha]_D^{25}$ +27.8 (c 0.11, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 1.18 (s, 3H), 1.18 - 1.61 (m, 14H), 2.05 (s, 3H), 1.88 - 1.97 (m, 1H), 2.63 (m, 1H), 3.91 (dd, *J* = 11.3, 8.5 Hz, 1H), 4.13 (dd, *J* = 11.3, 3.4 Hz, 1H), 4.43 (brs, 1H), 4.74 (s, 1H), 4.87 (s, 1H). ¹³C NMR (CDCl₃,400 MHz) δ : 16.2 (CH₃), 18.9 (CH₂), 20.5 (CH₂), 21.2 (CH), 21.6 (CH₃), 22.8 (CH₂), 23.7 (CH₃), 31.0 (CH₂), 33.5 (C), 33.6 (CH₃), 38.3 (C), 38.6 (CH₂), 40.5 (CH₂), 42.1 (CH₂), 53.4 (CH), 56.3 (CH), 68.0 (CH₂), 70.1 (CH), 79.1 (C), 107.9 (CH₂), 150.8 (C), 171.2 (C). IR (film): 1743, 1457, 1381, 1232, 1105, 1040 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₂H₃₆O₃Na (M+Na⁺) 371.2562, found: 371.2555.

(4S,5aR,7aS,11aS,11bR)-4-(Chloromethyl)-5a,8,8,11a-tetramethyl-3-methylenetetradecahydronaphtho [2,1-10,10,10,10], and a start of the start of the

b]oxepine (22). Pyridine (1 mL) and POCl₃ (0.5 mL) were added to a solution of 2 (100 mg, 0.326 mmol) previously cooled at 0° C and the mixture was kept stirring under argon atmosphere for 15 h. Then, the reaction was carefully quenched at 0° C with water (1mL), and ether was added (25 mL). The organic solution was washed with 10% HCl (3 x 10 mL) and brine (3 x 10 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% ether/hexane) to yield 22 (40 mg, 56%). $[\alpha]_D^{25}$ + 68.9 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 1.23 (s, 3H), 1.25 - 1.69 (m, 14H), 2.03 (dd, J = 11.9, 8.3 Hz, 1H), 2.62 (q, J= 10.1, 1H), 3.41 (dd, J = 11.2, 8.9 Hz, 1H), 3.53 1H), 4.91 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: 16.2 (CH₃), 18.9 (CH₂), 20.4 (CH₂), 21.6 (CH₃), 22.8 (CH₂), 23.7 (CH₃), 31.0 (CH₂), 33.4 (C), 33.6 (CH₃), 38.3 (C), 38.5 (CH₂), 40.5 (CH₂), 42.0 (CH₂), 49.1 (CH₂), 53.4 (CH), 56.4 (CH), 72.5 (CH), 79.3 (C), 108.5 (CH₂), 151.8 (C). IR (film): 1637, 1457, 1383, 1130, 1100, 1038, 946, 894, 746, 664 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₀H₃₃ClONa (M+Na⁺) 347.2118, found: 347.2131.

((*4S*,*5aR*,*7aS*,*11aS*,*11bR*)-5a,8,8,11a-Tetramethyl-3 methylenetetradecahydronaphtho[2,1-b]oxepin-4-yl)methanol

(23). LiBr (903 mg, 10.4 mmol) was added to a solution of 2 (80 mg, 2.6 mmol) in anhydrous DMF (10 mL) and the mixture was kept stirring at 70° C under argon atmosphere for 72 h. Then, the reaction was quenched with water (1 mL), and ether was added (30 mL). The organic solution was washed with water (4 x 25 mL) and brine (3 x 20 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% ether/hexane) to yield 23 (50 mg, 30%). Colorless oil. $[\alpha]_D^{25}$ + 70.9 (c 0.6, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.79 (s, 3H), 0.81 (s, 3H), 0.86 (s, 3H), 1.06 (ddd, J = 13.4, 13.4, 4.1Hz, 1H), 1.22 (s, 3H), 1.19 - 1.70 (m, 14H), 2.03 (ddd, J =10.7, 8.3, 1.5 Hz, 1H), 2.11 (brs, 1H), 2.57 (m, 1H), 3.37 (dd, J = 11.0, 9.0 Hz, 1H), 3.49 (dd, J = 11.0, 4.0 Hz, 1H), 4.31 (m, 1H), 4.65 (s, 1H), 4.82 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: 16.2 (CH₂), 18.9 (CH₂), 20.5 (CH₂), 21.6 (CH₃), 22.8 (CH₂), 23.9 (CH₃), 30.8 (CH₂), 33.5 (C), 33.6 (CH₃), 38.4 (C), 39.1 (CH₂), 40.5 (CH₂), 42.0 (CH₂), 53.5 (CH), 56.4 (CH), 66.2 (CH₂), 72.8 (CH), 79.3 (C), 107.0 (CH₂), 151.0 (C). IR (film): 3461, 1643, 1454, 1412, 1095, 1041, 888, 756 cm⁻¹. HRMS (FAB) m/z: calcd for $C_{20}H_{34}O_2Na$ (M+Na⁺) 329.2457, found: 329.2442.

Treatment of compound 2 with TMSOTf. Obtention of alcohol 23. N,N-Diisopropylethylamine (0.26 mL, 1.47 mmol) and TMSOTf (0.21 mL, 1.17 mmol) were added to a solution of 2 (300 mg, 0.98 mmol) in anhydrous CH_2Cl_2 (15 mL), and the mixture was kept stirring at 0° C under argon atmosphere for 5 min. Then, the reaction was carefully quenched with water (0.5 mL), and ether (20 mL) was added. The organic solution was washed with water (3 x 10 mL) and brine (2 x 10 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield alcohol 23 (359 mg, 97%) as colorless oil.

tert-Butyldimethyl(((4*S*,5a*R*,7a*S*,11a*S*,11b*R*)-5a,8,8,11atetramethyl-3-methylenetetradecahydronaphtho[2,1blavanin 4 rl)metharm)silana

b]oxepin-4-yl)methoxy)silane N,N-(24). Diisopropylethylamine (1.7 mL, 9.8 mmol) and TBSOTf (0.9 mL, 4.9 mmol) were added to a solution of 2 (1 g, 4.9 mmol) in anhydrous CH₂Cl₂ (30 mL), and the mixture was kept stirring at 0° C under argon atmosphere for 5 min. Then, the reaction was carefully quenched with water (2 mL), and ether (30 mL) was added. The organic solution was washed with water (3 x 10 mL) and brine (2 x 10 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield **24** (1.36 g, 99%) as colorless oil. $[\alpha]_D^{25}$ +45.9 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.06 (s, 6H), 0.78 (s, 3H), 0.82 (s, 3H), 0.86 (s, 3H), 0.89 (s, 9H), 1.12 (ddd, J = 13.5, 13.3, 4.0 Hz,1H), 1.13 (s, 3H), 1.21 - 1.67 (m, 13H), 1.97 (ddd, J = 9.2, 5.7, 1.4, 1H), 2.58 (q, J = 10 Hz, 1H), 3.48 (dd, J = 10.5, 5.0 Hz, 1H), 3.52 (dd, J = 10.5, 6.3 Hz, 1H),4.22 (t, J = 5.8 Hz, 1H), 4.69 (t, J = 1.36 Hz, 1H), 4.81 (d, J =0.8 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: -5.1 (CH₃), -4.8 (CH₃), 16.3 (CH₃), 18.6 (CH₂), 19.0 (C), 20.6 (CH₂), 21.6 (CH₃), 22.9 (CH₂), 23.8 (CH₃), 26.1 (3 CH₃), 31.0 (CH₂), 33.5 (CH₃), 33.6 (C), 38.3 (CH₂), 38.7 (C), 40.5 (CH₂), 42.1 (CH₂), 53.4 (CH), 56.4 (CH), 67.9 (CH₂), 73.3 (CH), 78.7 (C), 107.1 (CH₂), 151.9 (C). IR (film): 1461, 1381, 1252, 1122, 1085, 836, 775 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₆H₄₈O₂SiNa (M+Na⁺) 443.3321, found: 443.3312.

tert-Butyldimethyl(((2*R*,5a*S*,9a*S*)-6,6,9a-trimethyl-3methylenedecahydrobenzo[b]oxepin-2-yl)methoxy)silane

(25). N,N-Diisopropylethylamine (0.22 mL, 1.26 mmol) and TBSOTf (0.36 mL, 1.57 mmol) were added to a solution of 11 (250 mg, 1.05 mmol) in anhydrous CH₂Cl₂ (15 mL) cooled at 0 °C, and the mixture was kept stirring at this temperature under argon atmosphere for 15 min. Then, the reaction was carefully quenched with water (1 mL), and ether (20 mL) was added. The organic solution was washed with water (3 x 10 mL) and brine (2 x 10 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ethyl acetate/hexane) to yield 25 (359 mg, 97%) as colorless syrup. $[\alpha]_D^{25}$ -20.4 (c 0.12, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ: 0.05 (s, 3H), 0.07 (s, 3H), 0.82 (s, 3H), 0.88 (s, 3H), 0.89 (s, 9H), 1.20 (s, 3H), 1.59 - 1.40 (m, 9H), 2.60 (brdt, J = 15.2, 10.8 Hz, 2H), 3.56 - 3.45 (m, 2H), 4.22 (brdd, J = 6.2 Hz, 1H), 4.72 (d, J =1.6 Hz, 1H), 4.81 (d, J = 1.6 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃) δ: -5.0 (CH₃), -4.7 (CH₃), 18.6 (C), 20.8 (CH₂), 21.6

(CH₃), 22.8 (CH₃), 23.8 (CH₂), 26.1 (3 CH₃), 31.2 (CH₂), 33.6 (CH₃), 34.9 (C), 37.8 (CH₂), 42.0 (CH₂), 49.2 (CH), 67.9 (CH₂), 73.5 (CH), 78.6 (C), 107.3 (CH₂), 151.7 (C). IR (film): 1722, 1426, 1255, 1124, 1074, 960 cm⁻¹. HRMS (FAB) *m*/*z*: calcd for $C_{21}H_{40}O_2SiNa$ (M+Na⁺) 375.2695, found: 375.2709.

(4S,5aR,7aS,11aS,11bR)-4-(Chloromethyl)-5a,8,8,11a-tetramethyldodecahydronaphtho[2,1-b]oxepin-3(2H)-one

(26). Ozone stream was bubbled into a solution of 22 (80 mg, 0.246 mmol) in anhydrous CH₂Cl₂ previously cooled at -78° C for 1 h. When the reaction finished, an argon stream was bubbled for eliminate ozone excess. Then, PPh3 was added to the cooled solution and the mixture was kept stirring for 2 h. Solvent was evaporated to afford a crude product that was purified by flash chromatography on silica gel (10% ether/hexane) to yield **26** (66 mg, 83%). $[\alpha]_D^{25}$ +78.5 (c 0.11, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.79 (s, 3H), 0.85 (s, 3H), 0.86 (s, 3H), 1.25 (s, 3H), 1.40 - 1.78 (m, 14H), 2.18 (ddd, J = 11.4, 10.9, 2.0 Hz, 1H), 3.22 (q, J = 10.3 Hz, 1H), 3.63 (dd, J =11.2, 6.4 Hz, 1H), 3.67 (dd, J = 11.2, 2.8 Hz, 1H), 4.02 (dd, J = 6.2, 3.0 Hz, 1H). ¹³C NMR (CDCl3, 125 MHz) δ : 15.6 (CH₃), 18.4 (CH₂), 18.8 (CH₂), 20.3 (CH₂), 21.5 (CH₃), 23.5 (CH₃), 33.4 (C), 33.5 (CH₃), 38.0 (CH₂), 38.5 (CH₂), 38.7 (C), 40.3 (CH₂), 41.8 (CH₂), 45.6 (CH₂), 53.7 (CH), 56.3 (CH), 76.4 (CH), 80.1 (C), 215.6 (C). IR (film): 1747, 1697, 1616, 1457, 1370, 1222, 1125, 1056, 1009, 930, 771, 665 cm⁻¹. HRMS (FAB) m/z: calcd for C₁₉H₃₁ClO₂Na (M+Na⁺) 349.1910, found: 349.1902.

(3*R*,4*S*,5a*R*,7a*S*,11a*S*,11b*R*) -4- (Chloromethyl)-3,5a,8,8,11a-pentamethyltetradecahydronaphtho[2,1b]oxepin-3-ol (27a) and (3*S*,4*S*,5a*R*,7a*S*,11a*S*,11b*R*)-4-

(chloromethyl)pentamethyltetradecahydronaphtho[2,1-b]oxepin-3-ol

(27b). A CH₃MgBr solution (0.18 mL, 1.4 M THF/Toluene, 0.18 mmol) was added to a solution of 27 (120 mg, 0.36 mmol) in anhydrous THF (15 mL) previously cooled at -30° C and the mixture was kept stirring under argon atmosphere for 1 h. Then 10% HCl (1 mL) was added and the mixture was kept stirring for 5 min more. The solvent was evaporated and ether was added (30 mL). The organic solution was washed with water (3 x 10 mL) and brine (15 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (5% ether /hexane) to yield 27a (49 mg, 38%) and 27b (70 mg, 57%). **Compound 27a.** $[\alpha]_D^{25}$ +26.6 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.77 (s, 3H), 0.78 (s, 3H), 0.86 (s, 3H), 0.84 – 0.93 (m, 1H), 1.15 s, 3H), 1.18 (s, 3H), 1.23 – 1.84 (m, 15H), 3.21 (brs, 1H), 3.35 (dd, J = 11.0, 9.7 Hz, 1H), 3.80 (dd, J = 9.4, 1.8 Hz, 1H), 3.97 (dd, J = 11.0, 2.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) &: 16.2 (CH₃), 18.5 (CH₂), 19.1 (CH₂), 20.89 (CH₂), 21.1 (CH₃), 21.7 (CH₃), 24.1, (CH₃), 33.3 (C), 33.3 (CH₃), 39.0 (C), 39.3 (CH₂), 39.7 (C), 42.0 (CH₂), 45.6 (CH₂), 47.5 (CH₂), 56.3 (CH), 58.3 (CH), 75.3 (C), 76.0 (CH), 78.7 (C). HRMS (FAB) m/z: calcd for C₂₀H₃₅ClO₂Na (M+Na⁺) 365.2223, found: 365.2236. Compound 27b. $[\alpha]_D^{25}$ +7.9 (c 0.13, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.79 (s, 3H), 0.85 (s, 3H), 0.86 (s, 3H), 1.10 (ddd, J = 11.4, 10.9, 2.3 Hz, 1H), 1.25 (s, 3H), 1.36 (s, 3H), 1.40 - 1.78 (m, 14H), 2.18 (ddd, J = 11.4, 10.9, 2.0 Hz, 1H), 3.22 (q, J = 10.3 Hz, 1H), 3.63 (dd, J = 11.2, 6.4 Hz, 1H), 3.67 (dd, J = 11.2, 2.8 Hz, 1H), 4.02 (dd, J = 6.2, 3.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: 16.2 (CH₃), 18.1 (CH₂), 18.5 (CH₂), 20.9 (CH₂), 21.1

(CH₃), 24.1 (CH₃), 24.9 (CH₃), 33.3 (C), 33.30 (CH₃), 39.0 (C), 39.1 (CH₂), 39.6 (CH₂), 42.1 (CH₂), 44.8 (CH₂), 45.5 (CH₂), 56.3 (CH), 58.1 (CH), 72.7 (C), 74.4 (CH), 79.3 (C). HRMS (FAB) m/z: calcd for C₂₀H₃₅ClO₂Na (M+Na⁺) 365.2223, found: 365.2215.

(2S,4S,5aR,7aS,11aS,11bR)-4-(((*tert*-

Butyldimethylsilyl)oxy)methyl)-5a,8,8,11a-tetramethyl-3methylenetetradecabydronaphthe[2,1,bloyopin,2,al, (29)

methylenetetradecahydronaphtho[2,1-b]oxepin-2-ol (28). tert-Butyl hydroperoxide (0.22 mL, 1.2 mmol) was added to a solution of 24 (500 mg, 1.2 mmol) in anhydrous CH₂Cl₂ previously cooled at 0° C and the mixture was kept stirring under argon atmosphere for 5 min. Then, catalytic SeO₂ was added (1.3 mg, 0.12 mmol) and the mixture was kept stirring for 24 h. The solvent was evaporated, and ether was added (15 mL). The organic solution was washed with water (3 x 5 mL) and brine (5 mL), dried over anh. Na₂SO₄, and evaporated to afford a crude product that was purified by flash chromatography on silica gel (30% AcOEt /hexane) to yield 28 (400 mg, 83%). $[\alpha]_D^{25}$ +58.3 (c 0.12, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.04 (s, 6H), 0.77 (s, 3H), 0.82 (s, 3H), 0.84 (s, 3H), 0.88 (s, 9H), 1.11 (ddd, J = 13.4, 13.4, 4.0 Hz, 1H), 1.17 (s, 3H), 1.26 - 1.64 (m, 12H), 2.04 (ddd, J = 12.6, 12.6, 8.0 Hz, 1H), 3.52 (d, J = 10.5 Hz, 1H), 3.55 (s, 1H), 3.55 (d, J = 10.5Hz, 1H), 4.27 (brs, 1H), 4.81 (dd, J = 8.0, 8.0 Hz, 1H), 4.83 (s, 1H), 5.04 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: -5.2 (CH₃), -4.9 (CH₃), 16.0 (CH₃), 18.3 (C), 18.6 (CH₂), 20.3 (CH₂), 21.3 (CH₃), 23.4 (CH₃), 25.9 (3 CH₃), 33.20 (CH₂), 33.26 (C), 33.3 (CH₃), 37.5 (CH₂), 37.9 (C), 40.2 (CH₂), 41.8 (CH₂), 52.9 (CH), 56.0 (CH), 67.8 (CH₂), 69.1 (CH), 72.0 (CH), 78.0 (C), 104.3 (CH₂), 153.7 (C). IR (film): 3412, 1646, 1462, 1383, 1253, 1122, 836, 776 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₆H₄₈O₃SiNa (M+Na⁺) 459.3270, found: 459.3259.

(2S,4S,5aR,7aS,11aS,11bR)-4-(((Tert-

butyldimethylsilyl)oxy)methyl)-5a,8,8,11a-tetramethyl-3methylenetetradecahydronaphtho[2,1-b]oxepin-2-yl me-

thanesulfonate (29). MsCl (124 mg, 1.08 mmol) and pyridine (5 mL) were added to a solution of 28 (200 mg, 0.45 mmol) in anhydrous CH₂Cl₂ (15 mL), and the mixture was kept stirring under argon atmosphere for 12 h. Then, ether was added (50 mL) and the organic solution was washed with 10% HCl (10 mL), water (2 x 10 mL) and brine (10 mL), dried over anh. Na₂SO₄, and evaporate to yield **29** (210 mg, 91%). $[\alpha]_D^{25}$ -31.8 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.04 (s, 6H), 0.77 (s, 3H), 0.82 (s, 3H), 0.85 (s, 3H), 0.88 (s, 9H), 1.17 (s, 3H), 1.72-1.21 (m, 12H), 2.09-2.01 (m, 2H), 3.62 (d, J =10.5 Hz, 1H), 3.63 (d, J = 10.5 Hz, 1H), 4.27 (m, 1H), 4.83 (brs, 1H), 5.05 (brs, 1H), 5.50 (t, J = 7.9 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: -5.1 (2 CH₃), 16.0 (CH₃), 18.4 (C) 18.6 (CH₂), 20.2 (CH₂), 21.3 (CH₃), 23.5 (CH₃), 25.8 (3 CH₃), 31.5 (CH₂), 33.2 (C), 33.3 (CH₃), 37.3 (CH₂), 37.9 (C), 40.1 (CH₂), 41.7 (CH₂), 52.5 (CH₃), 52.8 (CH), 56.0 (CH), 67.9 (CH₂), 71.2 (CH), 78.3 (C), 80.3 (C), 107.1 (CH₂), 147.8 (C). IR (film): 1727, 1631, 1462, 1385, 1359, 1253, 1177, 1122, 1082, 954, 836, 761 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₇H₅₀O₅SSiNa (M+Na⁺) 537.3046, found: 537.3061.

(4aS,6aR,7aS,12aR,12bS)-4,4,6a,12b-Tetramethyl-1,2,3,4,4a,5,6,6a,7a,8,10,12,12a,12b-

tetradecahydrofuro[3,4-b]naphtho[1,2-f]oxepine (30). TBAF (74.6 mg, 0.28 mmol) was added to a solution of 29 (120 mg, 0.24 mmol) in anhydrous THF (10 mL), and the reflux mixture was kept stirring for 15 h. Then, the solvent was evaporated and ether was added (25 mL). The organic solution was washed with water (3 x1 0 mL) and brine (10 mL), dried over anh. Na₂SO₄, and evaporated to yield 30 (80 mg, 78%). [α]_D²⁵ -14.1 (c 0.14, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.80 (s, 6H), 0.88 (s, 3H), 0.91 (dd, *J* = 12.9, 3.9 Hz, 1H), 1.15 (ddd, J = 14.7, 13.4, 2.7 Hz, 1H), 1.24 (s, 3H), 1.31 -1.41 (m, 3H), 1.45 (dt, J = 13.3, 3.4 Hz, 1H), 1.56 - 1.79 (m, 5H), 1.90 (dd, J = 8.6, 2.8 Hz, 2H), 2.18 – 2.23 (m, 2H), 3.44 (t, J = 8.3 Hz, 1H), 4.06 (t, J = 8.1 Hz, 1H), 4.34 (dd, J = 12.7),2.2 Hz, 1H), 4.40 (brd, J = 12.7 Hz, 1H), 4.86 (brs, 1H), 5.53 (t, J = 2.7 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ : 16.1 (CH₃), 18.7 (CH₂), 20.6 (CH₂), 21.3 (CH₃), 23.1 (CH₃), 23.8 (CH₂), 33.3 (CH₃), 33.4 (C), 37.9 (CH₂), 38.8 (C), 39.9 (CH₂), 41.9 (CH₂), 55.8 (CH), 56.1 (CH), 69.9 (CH), 71.0 (CH₂), 72.1 (CH₂), 79.3 (C), 121.6 (CH), 141.8 (C). IR (film): 1732, 1461, 1384, 1106, 1060, 926, 755 cm⁻¹. HRMS (FAB) *m/z*: calcd for C₂₀H₃₂O₂Na (M+Na⁺) 327.2300, found: 327.2286.

(4aS,6aR,7aS,12aR,12bS)-4,4,6a,12b-Tetramethyl-1,3,4,4a,5,6,6a,7a,8,12,12a,12b-dodecahydrofuro[3,4-

b]naphtho[1,2-f]oxepin-10(2H)-one (31). Excess of PCC was added to a solution of **30** (50 mg, 0.165 mmol) in anhydrous CH₂Cl₂ (10 mL) and the reflux mixture was kept stirring under argon atmosphere for 12 h. When the reaction finished, the mixture was filtered on silica gel to afford a crude product that was purified by flash chromatography on silica gel (10% ether /hexane) to yield **31** (40 mg, 84%). $[\alpha]_D^{25}$ +6.4 (c 0.1, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ: 0.80 (s, 3H), 0.83 (s, 3H), 0.89 (s, 3H), 1.14 (ddd, J = 13.5, 13.4, 4.1 Hz, 1H), 1.26 (s, 3H), 1.29 - 1.87 (m, 11H), 2.37 (m, 1H), 2.48 (dd, J = 19.8, 6.3 Hz, 1H), 3.86 (dd, J = 8.9, 7.3 Hz, 1H), 4.47 (t, J = 8.1 Hz, 1H), 5.15 (m, 1H), 6.96 (brd, J = 6.4 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ: 16.0 (CH₃), 18.5 (CH₂), 20.5 (CH₂), 21.2 (CH₃), 22.7 (CH₃), 24.8 (CH₂), 33.3 (CH₃), 33.4 (C), 38.1 (CH₂), 38.9 (C), 39.8 (CH₂), 41.8 (CH₂), 55.2 (CH), 56.1 (CH), 66.7 (CH), 70.0 (CH₂), 80.3 (C), 131.8 (C), 144.1 (CH), 169.5 (C). IR (film): 1764, 1682, 1457, 1386, 1210, 1190, 1114, 1018, 772, 668 cm⁻¹. HRMS (FAB) m/z: calcd for C₂₀H₃₀O₃Na (M+Na⁺) 341.2093, found: 341.2105.

ASSOCIATED CONTENT

Supporting information

The Supporting Information is available free of charge on the ACS Publications website at DOI: ¹H and ¹³C NMR spectra for all new compounds.

AUTHOR INFORMATION

Corresponding Author

* E-mail: <u>rachid@ugr.es</u>; eamr@ugr.es.

Author Contributions

The manuscript was written through contributions of all authors. / All authors have given approval to the final version of the manuscript.

Funding Sources

Spanish Ministry of Economy and Competitiveness: Project CTQ2014-56611-R/BQU.

Regional Government of Andalucia (Spain): Project P11-CTS-7651.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank the Spanish Ministry of Economy and Competitiveness (Project CTQ2014-56611-R/BQU) and the Regional Government of Andalucia (Project P11-CTS-7651) for financial support and assistance provided to the FQM-348 group. This work is related to the Ph.D. Thesis of J. A. Gil.

REFERENCES

- For a review concerning the isolation, chemical and biotransformation routes of labdane-type diterpenes, including (-)-sclareol (1), see: Frija, L. M. T.; Frade, R. F. M.; Afonso, C. A. M. *Chem. Rev.* 2011, *111*, 4418-4452.
- (2) Martres, P.; Perfetti, P.; Zahra, J. P.; Waegell, B. *Tetra-hedron Lett* **1993**, *34*, 3127-3128.
- (3) Barton, D. H. R.; Shyamal, I.; Dennis, P.; Taylor, I. L.; Tse, C.-L. *Tetrahedron Lett* **1994**, *35*, 5801-5804.
- (4) Marcos, I. S.; Laderas, M.; Diez, D.; Basabe, P.; Moro, R. F.; Garrido, N. M.; Urones, J. G. *Tetrahedron Lett* 2003, 44, 5419-5422.
- (5) Decorzant, R; Vial, C.; Naef, F.; Whitesides, G. M. *Tetrahedron* **1987**, *43*, 1871-1879.
- (6) (a) Angelopoulou, D.; Demetzos, C.; Dimas, C.; Perdetzoglou, D.; Loukis, A. *Planta Med* 2001, 67, 168-171. (b) Garcez, F. R.; Garcez, W. S.; da Silva, A. F. G.; de Cássia Bazzo, R.; Resende, U. M. *J. Braz. Chem. Soc.* 2004, *15*, 767-772.
- (7) Alvarez-Manzaneda, E. J.; Chaboun, R.; Alvarez, E.; Cabrera, E.; Alvarez-Manzaneda, R.; Haidour, A.; Ramos, J. M. Synlett 2006, 12, 1829-1834.
- (8) (a) Mihailovic, M. L. J.; Cekovic, Z.; Maksimovic, V.; Jeremic, D.; Lorenc, L. J.; Mamuzic, R. I. *Tetrahedron* **1965**, *21*, 2799-2812. (b) Mihailovic, M. L. J.; Miloradovic, M. *Tetrahedron* **1966**, *22*, 723-738. (c) Mihailovic, M. L. J.; Gojkovic, S.; Milosavljevic, S. J. J. Serb. Chem. Soc. **1995**, *60*, 535-541.
- (9) For reviews concerning the synthesis of sevenmembered ring ethers, see: (a) Kleinke, A.; Webb, D.; Jamison, T. F. *Tetrahedron* 2012, 68, 6999-7018. (b) Piva, O. *Topics in Heterocyclic Chemistry* 2013, 36, 283-320.
- (10) (a) Pettit, G. R.; Herald, C. L.; Allen, M. S.; von Dreele, R. B.; Vanell, L. D.; Kao, J. P. Y.; Blake, W. J. Am. Chem. Soc. 1977, 99, 262-263. (b) von Dreele, R. B.; Kao, J. P. Y. Acta Cryst. 1980, B36, 2695-2698. (c) Capon, R.; Ghisalberti, E. L.; Jefferis, P. R.; Skelton; B. W.; White, A. H. Tetrahedron 1981, 37, 1613-1621. For a synthesis of this compound involving ring-closing metathesis see: (d) Couladuros, E. A.; Vidali, V. P. Chem. Eur. J. 2004, 10, 3822-3835.

- (11) (a) Paul, V. J.; Fenical, W. *Tetrahedron Lett.* **1980**, *21*, 2787-2790. For the synthesis of this type of compounds utilizing electrophilic cyclizations mediated by ion bromonium see: (b) Tanaka, A.; Suzuki, M. Agric. Biol. Chem, **1986**, *50*, 1069-1071.
- (12) Iliopoulou, D.; Mihopoulos, N.; Roussis, V.; Vagias, C. J. Nat. Prod. 2003, 66, 1225-1228.
- (13) (a) Potes, B. C. M.; Capon, R. J.; Faulkner, D. J. J. Org. Chem. 1992, 57, 2965-2967. For the synthesis of this compound see: (b) Basabe, P.; Bodero, O.; Marcos, I. S.; Díez, D.; Blanco, A.; de Román, M.; Urones, J. G. J. Org. Chem. 2009, 74, 7750-7754.
- (14) Killday, K. B.; Wright, A. E.; Jackson, R. H.; Sills, M. A. J. Nat. Prod. 1995, 58, 958-960.
- (15) Diols were easily prepared from the suitable natural terpene (cupressic acid, larixol, sclareol or α-cyclocitral). Hanane Bouanou, PhD Thesis, University of Granada, 2015.
- (16) Alkoxy-lead intermediates, involving tertiary hydroxyl groups, have been previously postulated in the LTA oxidation of unsaturated alcohols. See: (a) Preite, M. D.; Cuellar, M. A. *Chem. Commun.* 2004, 1970-1971. (b) Elkhayat, Z.; Safir, I.; Dakir, M.; Arseniyadis, S. *Tetrahedron: Asymmetry* 2007, *18*, 1589-1602. (c) Alvarez-Manzaneda, E. J.; Chaboun, R.; Alvarez, E.; Fernández, A.; Alvarez-Manzaneda, R.; Haidour, A.; Ramos, J. M.; Akhaouzan, A. *Chem. Commun.* 2012, *48*, 606-608.
- (17) Examples of reactions of Pb(IV) with both radical and cationic intermediates have been previously reported. For radical mechanisms examples see: (a) Tsunoi, S.; Ryu, I.; Okuda, T.; Tanaka, M.; Komatsu, M.; Sonoda, N. J. Am. Chem. Soc. 1998, 120, 8692-8701. (b) Paredes, M. D.; Alonso, R. Tetrahedron Lett. 1999, 40, 3973-3976. For cationic mechanisms examples see: (c) Cekovic, Z.; Saicic, R.; Mihailovic, M. L. Res. Chem. Interm. 1989, 11, 257-270. (d) Abet, V.; Castillo, R. R.; Aquino, M.; Gandara, Z.; Arseniyadis, S. Tetrahedron: Asymmetry 2015, 26, 981-1035.